Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | METAP1 | P53582 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237018 | 1.00 | ACHE (0.71) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL5237012 | 1.00 | ACHE (0.71) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL630841 | 0.87 | ACHE (0.58) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL29894949 | 0.83 | ACHE (1.00) | ACHECYP19A1METAP1HTR2AHTR2C | |
| SCHEMBL3860892 | 0.83 | ACHE (1.00) | ACHECYP19A1METAP1HTR2AHTR2C | |
| SCHEMBL3875408 | 0.83 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL13363970 | 0.83 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL6630846 | 0.83 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL992002 | 0.83 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL31040171 | 0.83 | CYP19A1 (0.59) | ACHECYP19A1METAP1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439841-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7196076-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | AR, SHBG, FSHR | ACHE 979/4885CYP19A1 13/4885METAP1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.